OTHER PUBLICATIONS & ABSTRACTS
Other Data
Evidence / Other
ASCO June 5 2019: Race and response to neoadjuvant chemotherapy
AUTHORS: Raquel Nunes, Femke de Snoo, Lisette Stork-Sloots, Tina Treece, Christa Dreezen, William Audeh DESCRIPTION: Race and response to neoadjuvant chemotherapy according to MammaPrint risk African-American (AA) women with breast cancer have a less favorable prognosis, likely due to differences in tumor biology. The Neoadjuvant BReast Cancer Symphony Trial (NBRST, Read More
2019 ASCO FLEX Poster
AUTHORS: Gordan Srkalovic, Adam Brufsky, Jennifer Crozier, Mehran Habibi, Pat Whitworth, Charles Cox, Ian Grady, Nina D’Abreo, Sarah Untch, Erin Yoder, William Audeh, FLEX Investigators Group DESCRIPTION: Clinical Trial in Progress: The FLEX Big Data Platform Explores New Gene Expression Profiles and Investigator-Initiated Protocols in Early Stage Breast Cancer Genomic Read More
Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis
PUBLICATION: Vol 115 No 3/4 (2019): South African Journal of Science. AUTHORS: Kathleen A. Grant; Ettienne J. Myburgh; Elizabeth Murray; Fredrieka M. Pienaar; Martin Kidd; Colleen A. Wright; Maritha J. Kotze SUMMARY: Neither single-gene genomic mRNA nor IHC reporting of ER and PR status can replace the combined use of Read More
2018 SABCS FLEX Trials in Progress Poster
AUTHORS: Adam M. Brufsky, Jennifer A. Crozier, Ian Grady, Thomas Lomis, Pat Whitworth, Esther Rehmus, Gordon Srkalovic, Laura Lee, Peter Blumencranz, Paul Baron, Blanche Mavromatis, Sarah Untch, Lisa Blumencranz, Tina Treece, Erin Yoder, William Audeh. DESCRIPTION: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Read More
BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2
AACR, Poster 2612 AUTHORS: Pei Rong Evelyn Lee, Zelos Zhu, Denise Wolf, Christina Yau, William Audeh, Annuska Glas, Lamorna Brown-Swigart, Gillian Hirst, Angela DeMichele, ISPY2 TRIAL Investigators, Laura Esserman and Laura van ‘t Veer DESCRIPTION: BluePrint Luminal subtype predicts non-response to HER2-targeted therapies in HR+/HER2+ I-SPY2 breast cancer patients BluePrint® Read More
Copy Number Profiling of MammaPrint Genes Reveals Association with the Prognosis of Breast Cancer Patients
PUBLICATION: J Breast Cancer. 2017 Sep;20(3):246-253. English. Published online Sep 22, 2017. https://doi.org/10.4048/jbc.2017.20.3.246 AUTHORS: Areej Fatima, Fomaz Tariq, Muhammad Faraz Arshad Malik, Muhammad Qasim, and Farhan Haq SUMMARY: DNA copy number variations (CNVs) in realtion to MammaPrint 70-genes (cell line and TCGA data). Read more: Copy Number Profiling of MammaPrint..._Fatima Read More
Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer
PUBLICATION: Biomark Insights. 2016; 11: 139–146. doi: 10.4137/BMI.S38435 AUTHORS: Inès J. Beumer, Marion Persoon, Anke Witteveen, Christa Dreezen, Suet-Feung Chin, Stephen-John Sammut, Mireille Snel, Carlos Caldas, Sabine Linn, Laura J. van ’t Veer, Rene Bernards, and Annuska M. Glas BACKGROUND MammaPrint® is a microarray-based gene expression test cleared by the Read More